Literature DB >> 15622242

Epidermal growth factor in Dupuytren's disease.

Katarzyna Augoff1, Józef Kula, Jerzy Gosk, Roman Rutowski.   

Abstract

The aim of this article was to show the participation of epidermal growth factor (EGF) in the pathogenesis of Dupuytren's disease (palmar contracture). The concentration of EGF in specimens obtained from 68 patients with Dupuytren's contracture and 14 controls was examined immunochemically with the use of enzyme-linked immunosorbent assay. The determined EGF concentration in pathologic aponeurosis with symptoms of Dupuytren's disease (median, 6.29 ng/g; range, 1.67 to 63.09 ng/g) showed significantly different values (p = 0.036) in comparison with the control group (median, 10.1 ng/g; range, 5.13 to 39.81 ng/g). The changes in EGF concentration were shown in tested groups of pathologic tissues that were formed according to the clinical stage of disease progression. The significantly lower concentration than that seen in the control group characterizes tissues with first and third degrees of palmar contracture progression (p = 0.025 and p = 0.018, respectively). In the group of patients with second-degree disease progression, the EGF level increased transiently. Nevertheless, in comparison with the other groups, the difference was not significant. The group with the fourth degree of the disease showed EGF concentrations that resembled the control values. The authors conclude that significant differences in levels of EGF concentration between contractured and normal fasciae may suggest the participation of this cytokine in the pathogenesis of Dupuytren's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15622242

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  7 in total

Review 1.  The fascia of the limbs and back--a review.

Authors:  Mike Benjamin
Journal:  J Anat       Date:  2009-01       Impact factor: 2.610

2.  Screening of candidate genes in fibroblasts derived from patients with Dupuytren's contracture using bioinformatics analysis.

Authors:  Haoyu Liu; Weitian Yin; Biao Liu; Yan Liu; Baofeng Guo; Zhuang Wei
Journal:  Rheumatol Int       Date:  2015-05-12       Impact factor: 2.631

Review 3.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

4.  Expression of VEGF, its receptors, and HIF-1α in Dupuytren's disease.

Authors:  Lukas A Holzer; Andrej Cör; Gerhard Pfandlsteiner; Gerold Holzer
Journal:  Acta Orthop       Date:  2013-07-03       Impact factor: 3.717

5.  Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts.

Authors:  Carola Krause; Peter Kloen; Peter Ten Dijke
Journal:  Fibrogenesis Tissue Repair       Date:  2011-06-28

6.  Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease.

Authors:  Helen B Forrester; Peter Temple-Smith; Seungmin Ham; David de Kretser; Graeme Southwick; Carl N Sprung
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

7.  Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture.

Authors:  Latha Satish; William A LaFramboise; David B O'Gorman; Sandra Johnson; Benjamin Janto; Bing Siang Gan; Mark E Baratz; Fen Z Hu; J Christopher Post; Garth D Ehrlich; Sandeep Kathju
Journal:  BMC Med Genomics       Date:  2008-04-23       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.